UiPath (NYSE:PATH) jumped 7% in premarket trading Thursday after the company reported better-than-expected Q4 earnings and issued upbeat guidance for the fiscal 2025.
For the fiscal Q4 2024, the software maker reported earnings per share (EPS) of $0.22, topping the consensus estimates of $0.16 forecast. Revenue came in at $405.25 million, exceeding the anticipated $383.66 million.
Moreover, UiPath reported a non-GAAP gross margin of 89%.
Looking ahead, the company projects its first-quarter 2025 revenue to be between $330 million and $335 million, slightly below the analyst consensus of $347.9 million.
Its annual recurring revenue (ARR) is estimated to be between $1.508 billion and $1.513 billion by April 30, 2024, and forecasts a non-GAAP operating income of around $55 million.
For the full year 2025, UiPath anticipates revenue in the range of $1.555 billion to $1.56 billion, outpacing the consensus projection of $1.53 billion.
The firm also projects its ARR to be between $1.725 billion and $1.730 billion by January 31, 2025.
“We delivered a strong close to the fiscal year with fourth quarter ARR growing 22 percent year-over-year to $1.464 billion, underscoring the meaningful outcomes our Business Automation Platform delivers for our customers,” said Rob Enslin, CEO of UiPath.
“The combination of UiPath’s AI and automation is the strategic change enabler for our customers that makes any digital transformation easier and faster, while empowering customers to innovate, adapt more quickly, and grow.”
JPMorgan analysts upgraded PATH from Neutral to Overweight following the report's release.
"We are upgrading UiPath shares to OW from Neutral as we anticipate the period of ARR growth decel transitioning into a stabilized growth trend while attachment to GenAI automation projects ramps amidst ongoing margin improvement," analysts said.
Citing "soft Q1 revenue guidance and cRPO trend," analysts do not expect PATH to rise significantly in the near-term, but rather see "an opportunity to accumulate shares at the current low $20s level."
Their price target on the stock was also raised from $22 to $28.